Completed PHASE4 INTERVENTIONAL 1-arm NCT01804244

A Single-Dose Pharmacokinetics and Safety Study of TMC278 in Healthy Adult Japanese Participants

An Open-label, Single-dose Study to Investigate the Pharmacokinetics and Safety of TMC278 After Oral Administration of TMC278 25 mg Tablet Under Fed Condition in Healthy Japanese Adult Male Subjects

Sponsor: Janssen Pharmaceutical K.K.

Conditions Healthy

Interventions TMC278

Updated 6 times since 2017 Last updated: Mar 18, 2014 Started: Mar 31, 2013 Primary completion: Mar 31, 2013 Completion: Mar 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01804244, this PHASE4 trial focuses on Healthy and remains completed. Sponsored by Janssen Pharmaceutical K.K., it has been updated 6 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Mar 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Pharmaceutical K.K.

Data source: Janssen Pharmaceutical K.K.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tokyo, Japan